Health Care Weekly: VA Suspends Harrow’s Out-of-State Compounding Licenses; CMS Reneges on Bone Growth Stimulator Payment Change; CMS Proposes Bundling Payment for Phosphate Binders into ESRD in 2027; OPPS Rule Includes Site Neutrality Measures, 340B Reimbursement Crackdown; CMS Seeks Stricter Enrollment Oversight for Home Health, DME; FDA 483s
The Health Care Weekly is a timely analysis of competition developments, policy changes and other updates that may affect medical and pharmaceutical markets. Key stories we’re following this week include: • Virginia suspends Harrow’s compounding licenses. • CMS walks back pricing change for bone growth stimulators but keeps device reclassification. • CMS seeks to bundle […]









































